Format

Send to

Choose Destination
Semin Thorac Cardiovasc Surg. 2013 Winter;25(4):328-34. doi: 10.1053/j.semtcvs.2013.11.001. Epub 2013 Nov 21.

Current readings: blood-based biomarkers for lung cancer.

Author information

1
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, New York University School of Medicine, New York, New York.
2
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, New York University School of Medicine, New York, New York. Electronic address: William.Rom@nyumc.org.

Abstract

Lung cancer is the leading cause of cancer deaths worldwide largely owing to diagnosis of the disease at an advanced stage. Recent advances in blood-based biomarker research have the potential to reduce mortality by providing a means for detecting lung cancer at an earlier stage. Since the publication of the National Lung Cancer Screening Trial demonstrating reduction in mortality with computed tomography (CT) scan screening, the U.S. Preventive Services Task Force has released a draft statement recommending annual low-dose CT scan screening for high-risk patients. However, CT screening has a high false-positive rate leading to the need for additional imaging and invasive procedures. In this article, we review recent literature on blood-based lung cancer biomarkers that we believe will have a significant role in enhancing screening efficacy in the near future.

KEYWORDS:

autoantibodies; biomarkers; early diagnosis; genomics; lung cancer; microRNA; proteomics

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center